Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche's Elecsys® Alzheimer’s disease CSF assays have received FDA 510(k) clearance, enhancing diagnosis accuracy for Alzheimer's patients over 55. These assays, available on cobas analyzers, offer lower costs and broader accessibility, aiming to diagnose up to 75% of undetected cases globally. They align with the demand for Alzheimer’s therapies and achieve 90% concordance with amyloid PET scans. By measuring key biomarkers, these tests facilitate early detection and potential treatment pathways, with scalability to meet future healthcare needs.
Roche received Emergency Use Authorization (EUA) from the FDA for its cobas® MPXV test, designed for the qualitative detection of monkeypox virus DNA in patient lesion swabs. This test, intended for use with cobas® 6800/8800 Systems, is notable because it evaluates actual patient samples rather than just laboratory-formulated samples. The dual-target approach enhances its reliability against mutations, enabling quicker diagnoses and treatment access, which is crucial as monkeypox symptoms mimic other illnesses.
Jnana Therapeutics has announced a second collaboration with Roche to discover small molecule drugs targeting cancer, immune-mediated, and neurological diseases. Under the agreement, Jnana will receive an upfront payment of $50 million and could earn milestone payments exceeding $2 billion. Jnana will focus on discovery and preclinical activities while Roche will handle development and commercialization. This partnership builds on their existing collaboration targeting SLC metabolite transporters, showcasing their strategic alignment in addressing high unmet medical needs.
Genentech, part of the Roche Group (RHHBY), reported that its Phase III GRADUATE I and II studies for the Alzheimer’s treatment gantenerumab failed to meet primary endpoints for slowing clinical decline in early Alzheimer’s patients. The beta-amyloid removal was lower than anticipated. Despite this setback, gantenerumab was well tolerated. Results of the study, involving 1,965 participants, showed non-significant clinical decline reductions of 8% and 6% in the two studies compared to placebo. Genentech remains committed to Alzheimer’s research and diagnostics.
Roche announced that its Phase III GRADUATE studies of gantenerumab in early Alzheimer’s disease did not meet primary endpoints for slowing clinical decline. The results showed a relative reduction in clinical decline of only 8% and 6% in two separate trials, which were not statistically significant. Additionally, the beta-amyloid removal levels were lower than anticipated. Despite these setbacks, Roche remains committed to the Alzheimer’s community and plans to present topline findings at the upcoming CTAD Conference on November 30, 2022.
Roche Diagnostics has launched the Pilot® COVID-19 At-Home Test, now available over-the-counter nationwide. This first over-the-counter test is designed for easy self-collection using an anterior nasal swab, delivering results in as little as 20 minutes. Authorized by the FDA under emergency use, the test boasts a relative sensitivity of 93.2% and a specificity of 100%. It is accessible at major retailers such as CVS and Amazon, enhancing testing convenience for individuals exposed to COVID-19. The initiative aligns with CDC guidance to mitigate virus spread.
Roche announced the early termination of the STRONG-HF study, demonstrating significant efficacy in reducing all-cause mortality and heart failure readmissions in patients after acute heart failure. The study highlighted the effectiveness of rapid up-titration of therapies and close follow-up, utilizing the Roche Elecsys NT-proBNP biomarker. Key results included an absolute risk reduction of 8.1% and a relative risk reduction of 34% in adverse outcomes at six months. Quality of life improved in the high-intensity care group. The findings could lead to a shift in heart failure management protocols.
Roche has launched its digital health portfolio under the navify brand, showcasing next-generation software solutions aimed at improving healthcare delivery. Debuted at HLTH 2022 in Las Vegas, the navify portfolio leverages analytics and data science to enhance operational processes and support clinical decision-making. The initiative aims to address interoperability issues in healthcare, potentially saving an estimated $30 billion in the US. Roche's commitment to personalized healthcare and digital transformation continues with over 30 digital solutions available globally.
Roche (OTCQX: RHHBY) announced significant findings from its haematology portfolio at the 64th ASH Annual Meeting. Key highlights include interim phase III HAVEN 7 data confirming Hemlibra’s efficacy for infants with severe haemophilia A, new data on Polivy's potential in diffuse large B-cell lymphoma, and promising results for bispecific antibodies Lunsumio and glofitamab. Additionally, crovalimab data shows efficacy in paroxysmal nocturnal haemoglobinuria. Roche focuses on innovative therapies addressing critical needs in blood disorders.
Genentech, part of Roche Group, announced new data from its hematology portfolio at the 64th ASH Annual Meeting, highlighting the efficacy of Hemlibra in infants with severe hemophilia A. New findings also support Polivy's potential in treating previously untreated diffuse large B-cell lymphoma (DLBCL). Additional insights were shared on bispecific antibodies mosunetuzumab and glofitamab, demonstrating promising results in lymphoma treatment. Furthermore, crovalimab showed effectiveness in paroxysmal nocturnal hemoglobinuria. These advancements emphasize Genentech's commitment to addressing unmet medical needs in blood disorders.